Foundry Partners LLC Buys 331 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Foundry Partners LLC lifted its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 10.9% in the third quarter, according to its most recent filing with the SEC. The fund owned 3,362 shares of the specialty pharmaceutical company’s stock after acquiring an additional 331 shares during the period. Foundry Partners LLC’s holdings in Jazz Pharmaceuticals were worth $375,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Versant Capital Management Inc raised its stake in shares of Jazz Pharmaceuticals by 13,450.0% during the second quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock worth $29,000 after acquiring an additional 269 shares in the last quarter. Itau Unibanco Holding S.A. bought a new position in shares of Jazz Pharmaceuticals during the 2nd quarter valued at $29,000. EverSource Wealth Advisors LLC raised its position in Jazz Pharmaceuticals by 55.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after purchasing an additional 97 shares during the period. GAMMA Investing LLC lifted its stake in Jazz Pharmaceuticals by 65.5% in the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock worth $31,000 after purchasing an additional 116 shares during the last quarter. Finally, Gladius Capital Management LP purchased a new stake in Jazz Pharmaceuticals during the second quarter valued at about $33,000. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, SVP Mary Elizabeth Henderson sold 1,410 shares of the business’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $108.30, for a total transaction of $152,703.00. Following the sale, the senior vice president now owns 14,531 shares in the company, valued at approximately $1,573,707.30. The trade was a 8.85 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Neena M. Patil sold 3,700 shares of the company’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $123.41, for a total transaction of $456,617.00. Following the completion of the sale, the executive vice president now directly owns 33,048 shares in the company, valued at $4,078,453.68. This represents a 10.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 6,110 shares of company stock worth $720,160. Company insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ opened at $126.67 on Friday. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. Jazz Pharmaceuticals plc has a 1 year low of $99.06 and a 1 year high of $134.17. The company’s 50-day moving average is $113.29 and its 200 day moving average is $110.62. The stock has a market capitalization of $7.66 billion, a P/E ratio of 17.84, a P/E/G ratio of 0.98 and a beta of 0.57.

Analyst Upgrades and Downgrades

JAZZ has been the topic of several analyst reports. Wells Fargo & Company decreased their price objective on Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating on the stock in a report on Thursday, August 1st. TD Cowen decreased their price target on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. Piper Sandler reissued an “overweight” rating and set a $163.00 price objective (down previously from $166.00) on shares of Jazz Pharmaceuticals in a research note on Thursday. Robert W. Baird lifted their target price on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research note on Monday, November 18th. Finally, JPMorgan Chase & Co. upped their price target on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an “overweight” rating in a report on Monday, August 19th. Three equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $175.33.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.